BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Larrubia JR, Moreno-Cubero E, Miquel J, Sanz-de-Villalobos E. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015; 21(12): 3480-3491 [PMID: 25834312 DOI: 10.3748/wjg.v21.i12.3480]
URL: https://www.wjgnet.com/1007-9327/full/v21/i12/3480.htm
Number Citing Articles
1
Richard Barnard, Abha Chopra, Ian James, John Blinco, Mark W Watson, Cassandra B Jabara, Daria Hazuda, Stanley M Lemon, Simon Mallal, Silvana Gaudieri. Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance ScreeningAntiviral Therapy 2016; 21(7): 567 doi: 10.3851/IMP3056
2
Elia Moreno-Cubero, Juan-Ram&oacute;n Larrubia. Specific CD8<sup>+</sup> T cell response immunotherapy for hepatocellular carcinoma and viral hepatitisWorld Journal of Gastroenterology 2016; 22(28): 6469-6483 doi: 10.3748/wjg.v22.i28.6469
3
Hala S. El-Rebey, Asmaa G. Abdou, Mervat M. Sultan, Shymaa H. Ibrahim, Nanis S. Holah. The Profile and Role of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: An Immunohistochemical StudyApplied Immunohistochemistry & Molecular Morphology 2021; 29(3): 188 doi: 10.1097/PAI.0000000000000865
4
Ichiro Tamaki, Toshimi Kaido, Shintaro Yagi, Yoshihide Ueda, Etsuro Hatano, Hideaki Okajima, Shinji Uemoto. Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four casesSurgical Case Reports 2015; 1(1) doi: 10.1186/s40792-015-0127-0
5
Doaa A. Ghareeb, Eiman H. Elwakeel, Rowaida Khalil, Mina S. Aziz, Maha A. El demellawy. Investigation of the Immunomodulatory effect of Berberis vulgaris on core-pulsed dendritic cell vaccineBMC Complementary and Alternative Medicine 2016; 16(1) doi: 10.1186/s12906-016-1327-2
6
Li-Jing Qin, Zhang Lu, Zhong-Hua Zheng, Xiu-Hong Zhong. Research progress of natural products interfering with cell signaling pathway in liver fibrosisJournal of Asian Natural Products Research 2022; 24(1): 15 doi: 10.1080/10286020.2021.1883003
7
Saeid Najafi Fard, Ivan Schietroma, Giuseppe Corano Scheri, Noemi Giustini, Sara Serafino, Eugenio Nelson Cavallari, Claudia Pinacchio, Gabriella De Girolamo, Giancarlo Ceccarelli, Carolina Scagnolari, Vincenzo Vullo, Gabriella d’Ettorre. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patientsClinics and Research in Hepatology and Gastroenterology 2018; 42(4): 319 doi: 10.1016/j.clinre.2017.11.006
8
Miguel Jim&eacute;nez-P&eacute;rez, Roc&iacute;o Gonz&aacute;lez-Grande, Pilar España Contreras, Isabel Pinazo Mart&iacute;nez, Jes&uacute;s de la Cruz Lombardo, Ra&uacute;l Olmedo Mart&iacute;n. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceWorld Journal of Gastroenterology 2016; 22(29): 6573-6581 doi: 10.3748/wjg.v22.i29.6573
9
C. Carlton‐Smith, J. A. Holmes, S. Naggie, A. Lidofsky, G. M. Lauer, A. Y. Kim, R. T. Chung. IFN‐free therapy is associated with restoration of type I IFN response in HIV‐1 patients with acute HCV infection who achieve SVRJournal of Viral Hepatitis 2018; 25(5): 465 doi: 10.1111/jvh.12836
10
Grenda Leite Pereira, Andréa Monteiro Tarragô, Walter Luiz Lima Neves, Pedro Vieira da Silva Neto, Priscila Sarmento de Souza, Juliana dos Santos Affonso, Keyla Santos de Sousa, Jéssica Albuquerque da Silva, Allyson Guimarães Costa, Flamir da Silva Victoria, Marilu Barbieri Victoria, Adriana Malheiro. Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected PatientsMediators of Inflammation 2019; 2019: 1 doi: 10.1155/2019/4738237
11
Chao Zhang, Xiao-mei Wang, Shu-ran Li, Trix Twelkmeyer, Wei-hong Wang, Sheng-yuan Zhang, Shu-feng Wang, Ji-zheng Chen, Xia Jin, Yu-zhang Wu, Xin-wen Chen, Sheng-dian Wang, Jun-qi Niu, Hai-rong Chen, Hong Tang. NKG2A is a NK cell exhaustion checkpoint for HCV persistenceNature Communications 2019; 10(1) doi: 10.1038/s41467-019-09212-y
12
S. Shrivastava, E. Wilson, B. Poonia, L. Tang, A. Osinusi, A. Kohli, S. Kottilil. Augmentation of hepatitis C virus‐specific immunity and sustained virologic responseJournal of Viral Hepatitis 2017; 24(9): 742 doi: 10.1111/jvh.12702
13
Noy Ashkenazy, Carol L. Karp, Gaofeng Wang, Carolina Mercado Acosta, Anat Galor. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous NeoplasiaCornea 2017; 36(4): 506 doi: 10.1097/ICO.0000000000001153
14
Sylwia Osuch, Karin J. Metzner, Kamila Caraballo Cortés. Reversal of T Cell Exhaustion in Chronic HCV InfectionViruses 2020; 12(8): 799 doi: 10.3390/v12080799
15
Pier-Angelo Tovo, Carmelina Calitri, Carlo Scolfaro, Clara Gabiano, Silvia Garazzino. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progressionWorld Journal of Gastroenterology 2016; 22(4): 1382-1392 doi: 10.3748/wjg.v22.i4.1382
16
Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang, Fu-Sheng Wang. Current progress in host innate and adaptive immunity against hepatitis C virus infectionHepatology International 2017; 11(4): 374 doi: 10.1007/s12072-017-9805-2
17
Mohamad S. Hakim, Nofri Rahmadika, Rizka O. A. Jariah. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapyReviews in Medical Virology 2020; 30(2) doi: 10.1002/rmv.2094